SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
SCHEDULE 13G
(RULE 13D-102)
INFORMATION STATEMENT PURSUANT TO RULE 13D-1
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT)
TITAN PHARMACEUTICALS, INC.
---------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
888314101
---------
(CUSIP Number)
December 31, 2001
-----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
CUSIP No. 888314101 Page 1 of 7 Pages
1) Names of Reporting Persons
IRS Identification No. Of Above Persons
The PNC Financial Services Group, Inc. 25-1435979
2) Check the Appropriate Box if a Member of a Group (See Instructions)
a) [ ]
b) [ ]
3) SEC USE ONLY
4) Citizenship or Place of Organization Pennsylvania
Number of Shares 5) Sole Voting Power *
*See the response to Item 5.
Beneficially Owned 6) Shared Voting Power *
*See the response to Item 5.
By Each Reporting 7) Sole Dispositive Power *
*See the response to Item 5.
Person With 8) Shared Dispositive Power *
*See the response to Item 5.
9) Aggregate Amount Beneficially Owned by Each Reporting Person *
*See the response to Item 5.
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
See Instructions [ ]
11) Percent of Class Represented by Amount in Row (9) *
*See the response to Item 5.
12) Type of Reporting Person (See Instructions) HC
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
SCHEDULE 13G
(RULE 13D-102)
INFORMATION STATEMENT PURSUANT TO RULE 13D-1
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT)
TITAN PHARMACEUTICALS, INC.
---------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
888314101
---------
(CUSIP Number)
December 31, 2001
-----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
CUSIP No. 888314101 Page 2 of 7 Pages
1) Names of Reporting Persons
IRS Identification No. Of Above Persons
PNC Bancorp, Inc. 51-0326854
2) Check the Appropriate Box if a Member of a Group (See Instructions)
a) [ ]
b) [ ]
3) SEC USE ONLY
4) Citizenship or Place of Organization Delaware
Number of Shares 5) Sole Voting Power *
*See the response to Item 5.
Beneficially Owned 6) Shared Voting Power *
*See the response to Item 5.
By Each Reporting 7) Sole Dispositive Power *
*See the response to Item 5.
Person With 8) Shared Dispositive Power *
*See the response to Item 5.
9) Aggregate Amount Beneficially Owned by Each Reporting Person *
*See the response to Item 5.
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
See Instructions [ ]
11) Percent of Class Represented by Amount in Row (9) *
*See the response to Item 5.
12) Type of Reporting Person (See Instructions) HC
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
SCHEDULE 13G
(RULE 13D-102)
INFORMATION STATEMENT PURSUANT TO RULE 13D-1
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT)
TITAN PHARMACEUTICALS, INC.
---------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
888314101
---------
(CUSIP Number)
December 31, 2001
-----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
CUSIP No. 888314101 Page 3 of 7 Pages
1) Names of Reporting Persons
IRS Identification No. Of Above Persons
PNC Bank, National Association 22-1146430
2) Check the Appropriate Box if a Member of a Group (See Instructions)
a) [ ]
b) [ ]
3) SEC USE ONLY
4) Citizenship or Place of Organization United States
Number of Shares 5) Sole Voting Power *
*See the response to Item 5.
Beneficially Owned 6) Shared Voting Power *
*See the response to Item 5.
By Each Reporting 7) Sole Dispositive Power *
*See the response to Item 5.
Person With 8) Shared Dispositive Power *
*See the response to Item 5.
9) Aggregate Amount Beneficially Owned by Each Reporting Person *
*See the response to Item 5.
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
See Instructions [ ]
11) Percent of Class Represented by Amount in Row (9) *
*See the response to Item 5.
12) Type of Reporting Person (See Instructions) BK
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
SCHEDULE 13G
(RULE 13D-102)
INFORMATION STATEMENT PURSUANT TO RULE 13D-1
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT)
TITAN PHARMACEUTICALS, INC.
---------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
888314101
---------
(CUSIP Number)
December 31, 2001
-----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
CUSIP No. 888314101 Page 4 of 7 Pages
1) Names of Reporting Persons
IRS Identification No. Of Above Persons
BlackRock Advisors, Inc. 23-2784752
2) Check the Appropriate Box if a Member of a Group (See Instructions)
a) [ ]
b) [ ]
3) SEC USE ONLY
4) Citizenship or Place of Organization Delaware
Number of Shares 5) Sole Voting Power *
*See the response to Item 5.
Beneficially Owned 6) Shared Voting Power *
*See the response to Item 5.
By Each Reporting 7) Sole Dispositive Power *
*See the response to Item 5.
Person With 8) Shared Dispositive Power *
*See the response to Item 5.
9) Aggregate Amount Beneficially Owned by Each Reporting Person *
*See the response to Item 5.
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
See Instructions [ ]
11) Percent of Class Represented by Amount in Row (9) *
*See the response to Item 5.
12) Type of Reporting Person (See Instructions) IA
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
SCHEDULE 13G
(RULE 13D-102)
INFORMATION STATEMENT PURSUANT TO RULE 13D-1
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(FINAL AMENDMENT)
TITAN PHARMACEUTICALS, INC.
---------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
888314101
---------
(CUSIP Number)
December 31, 2001
-----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
CUSIP No. 888314101 Page 5 of 7 Pages
1) Names of Reporting Persons
IRS Identification No. Of Above Persons
BlackRock Financial Management, Inc. 13-3806691
2) Check the Appropriate Box if a Member of a Group (See Instructions)
a) [ ]
b) [ ]
3) SEC USE ONLY
4) Citizenship or Place of Organization Delaware
Number of Shares 5) Sole Voting Power *
*See the response to Item 5.
Beneficially Owned 6) Shared Voting Power *
*See the response to Item 5.
By Each Reporting 7) Sole Dispositive Power *
*See the response to Item 5.
Person With 8) Shared Dispositive Power *
*See the response to Item 5.
9) Aggregate Amount Beneficially Owned by Each Reporting Person *
*See the response to Item 5.
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
See Instructions [ ]
11) Percent of Class Represented by Amount in Row (9) *
*See the response to Item 5.
12) Type of Reporting Person (See Instructions) IA
Page 6 of 7 Pages
ITEM 5 - OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
Each reporting person has ceased to own beneficially more than 5% of
the stock of the issuer.
ITEM 10 - CERTIFICATION:
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and held in the ordinary
course of business and were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
Page 7 of 7 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 12, 2002
-----------------------------------------------------------------------
Date
By: /s/ Robert L. Haunschild
-----------------------------------------------------------------------
Signature - The PNC Financial Services Group, Inc.
Robert L. Haunschild, Senior Vice President and Chief Financial Officer
-----------------------------------------------------------------------
Name & Title
February 12, 2002
-----------------------------------------------------------------------
Date
By: /s/ James B. Yahner
-----------------------------------------------------------------------
Signature - PNC Bancorp, Inc.
James B. Yahner, Vice President
-------------------------------
Name & Title
February 12, 2002
-----------------------------------------------------------------------
Date
By: /s/ Thomas R. Moore
-----------------------------------------------------------------------
Signature - PNC Bank, National Association
Thomas R. Moore, Secretary
--------------------------
Name & Title
February 12, 2002
-----------------------------------------------------------------------
Date
By: /s/ William J. Wykle
-----------------------------------------------------------------------
Signature - BlackRock Advisors, Inc.
William J. Wykle, Managing Director
-----------------------------------
Name & Title
February 12, 2002
-----------------------------------------------------------------------
Date
By: /s/ William J. Wykle
-----------------------------------------------------------------------
Signature - BlackRock Financial Management, Inc.
William J. Wykle, Managing Director
-----------------------------------
Name & Title
AN AGREEMENT TO FILE A JOINT STATEMENT
WAS PREVIOUSLY FILED AS EXHIBIT A TO SCHEDULE 13G